KALA BIO, Inc. (KALA) Q3 2021 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kala Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:03.192 Good morning and welcome to the COLA Pharmaceuticals conference call to review its third 00:00:03.192 -- 00:00:06.235 quarter financial results in the acquisition of Combangio. 00:00:06.235 -- 00:00:09.319 Please note that this live presentation that was designed to accompany this conference 00:00:09.319 -- 00:00:13.042 call is available on COLA's website, colarx.com, 00:00:13.042 -- 00:00:15.785 as well as through the webcast player. 00:00:15.785 -- 00:00:18.288 At this time, all participants are in a listen-only mode. 00:00:18.288 -- 00:00:21.591 Following management's prepared remarks, a Q&A session will be held. 00:00:21.591 -- 00:00:23.755 As a reminder, this call is being recorded. 00:00:23.755 -- 00:00:27.277 I would now like to turn the call over to Jill Steyer, Executive Director, Investor Relations 00:00:27.277 -- 00:00:29.278 and Corporate Communications for Cala Pharmaceuticals. 00:00:29.278 -- 00:00:29.758 Please proceed. 00:00:29.758 -- 00:00:31.840 Jill Steyer 00:00:31.840 -- 00:00:36.022 Thank you, Operator, and thank you all for participating in today's call. 00:00:36.022 -- 00:00:40.525 Earlier today, we issued two press releases, one announcing our third quarter financial 00:00:40.525 -- 00:00:45.788 results and recent business highlights, and the other announcing our acquisition of Cambagio 00:00:45.788 -- 00:00:49.198 and its lead asset, CNB 012, 00:00:49.209 -- 00:00:52.200 which we have renamed KPI 012. 00:00:52.432 -- 00:00:57.637 a novel cell-free secretome therapy currently in clinical development for persistent 00:00:57.637 -- 00:01:02.761 cornelial epithelial defect. Both releases, along with the slides we will be reviewing 00:01:02.761 -- 00:01:09.706 on today's call, are available on the investor secti...